REDWOOD CITY, Calif., Sept. 6, 2011 /PRNewswire/ -- Pearl Therapeutics was named by FierceBiotech today as one of 2011's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's ninth annual Fierce 15 selection.
"Pearl's veteran team has done a super job of raising the funds and doing clinical research to advance PT003 – an inhaled LAMA/LABA combination therapy – toward the market," says Ryan McBride, the executive editor for FierceBiotech. "I believe the company is positioned well to gain marketing partners for the treatment."
Chuck Bramlage, Pearl's chief executive officer continued, "Earlier in 2011, following our $69 million Series C financing, we were named by FierceBiotech to the list of 15 top venture capital deals in biotechnology. Today's Fierce 15 award speaks not only to our fundraising ability, but to the commitment, expertise and passion with which the Pearl team pursues product development. I look forward to continuing to work with this exceptional team in our development of our lead COPD candidate, PT003, and living up to the 'fierce' moniker in fighting major respiratory ailments."
An internationally recognized daily newsletter reaching more than 90,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick, authoritative briefing on the day's top stories. Every year FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
The Fierce 15 celebrates the spir
|SOURCE Pearl Therapeutics|
Copyright©2010 PR Newswire.
All rights reserved